FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors.
Saved in:
| Title: | FUT8 Is a Critical Driver of Prostate Tumour Growth and Can Be Targeted Using Fucosylation Inhibitors. |
|---|---|
| Authors: | Bastian K; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Orozco-Moreno M; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Thomas H; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'gorman Building, Newcastle University, Newcastle upon Tyne, UK., Hodgson K; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Visser EA; Synthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, the Netherlands., Rossing E; Synthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, the Netherlands., Pijnenborg JFA; GlycoTherapeutics B.V, Nijmegen, the Netherlands., Eerden N; GlycoTherapeutics B.V, Nijmegen, the Netherlands., Wilson L; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'gorman Building, Newcastle University, Newcastle upon Tyne, UK., Saravannan H; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Hanley O; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Grimsley G; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina, USA., Frame F; Cancer Research Unit, Department of Biology, University of York, North Yorkshire, UK., Peng Z; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Knight B; NIHR Exeter Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., McCullagh P; Department of Pathology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., McGrath J; Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK., Crundwell M; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK., Harries L; Institute of Biomedical and Clinical Sciences, Medical School, College of Medicine and Health, University of Exeter, Exeter, UK., Maitland NJ; Cancer Research Unit, Department of Biology, University of York, North Yorkshire, UK., Heer R; Newcastle University Centre for Cancer, Translational and Clinical Research Institute, Paul O'gorman Building, Newcastle University, Newcastle upon Tyne, UK., Wang N; The Mellanby Centre for Musculoskeletal Research, Division of Clinical Medicine, The University of Sheffield, Sheffield, UK.; Leicester Cancer Research Centre, Department of Genetics, Genomics, and Cancer Sciences, University of Leicester, Leicester, UK., Goddard-Borger ED; The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.; Department of Medical Biology, University of Melbourne, Parkville, Victoria, Australia., Guerrero RH; University of Zaragoza, Zaragoza, Spain.; Copenhagen Center for Glycomics, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark., Boltje TJ; Synthetic Organic Chemistry, Institute for Molecules and Materials, Radboud University, Nijmegen, the Netherlands., Drake RR; Department of Cell and Molecular Pharmacology, Medical University of South Carolina, Charleston, South Carolina, USA., Scott E; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Elliott DJ; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK., Munkley J; Newcastle University Centre for Cancer, Newcastle University Institute of Biosciences, Newcastle, UK. |
| Source: | Cancer medicine [Cancer Med] 2025 May; Vol. 14 (10), pp. e70959. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2045-7634 |
|---|---|
| DOI: | 10.1002/cam4.70959 |
